DNA & RNA Banking Services

Global DNA & RNA Banking Services Market to Reach US$11.5 Billion by 2030

The global market for DNA & RNA Banking Services estimated at US$8.6 Billion in the year 2024, is expected to reach US$11.5 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Transportation Service, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Processing Service segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 4.8% CAGR

The DNA & RNA Banking Services market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global DNA & RNA Banking Services Market – Key Trends & Drivers Summarized

Is the Surge in Genomic Research Revolutionizing the DNA & RNA Banking Landscape?

The exponential growth in genomic research and its expanding role in personalized medicine have become the cornerstone driving the rapid evolution of DNA and RNA banking services globally. As the fields of genomics, transcriptomics, and pharmacogenomics continue to flourish, the demand for high-quality, well-preserved nucleic acid samples has surged. Institutions involved in drug discovery, disease modeling, and biomarker identification rely heavily on biobanks that offer secure, long-term storage of genetic material. DNA and RNA banking services have thus emerged as a critical support infrastructure for researchers, healthcare providers, and biotechnology firms. This surge is also influenced by the increasing need for population-scale genomic databases that help identify genetic predispositions to chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions. Governments and private organizations alike are investing in large-scale biobanking initiatives to collect and analyze genetic information across diverse populations. These services provide standardized protocols for sample collection, processing, storage, and retrieval—ensuring the integrity and reproducibility of research findings. Additionally, the COVID-19 pandemic underscored the importance of rapid genomic surveillance and highlighted the need for robust RNA preservation systems, further emphasizing the critical role these services play. As a result, biobanking facilities are now being designed with advanced automation, cryogenic storage capabilities, and digital inventory management systems to meet the rising expectations for speed, security, and scalability. The convergence of precision medicine, artificial intelligence, and genomics continues to push the boundaries of data-driven healthcare, making DNA and RNA banking a central pillar in the biomedical innovation ecosystem.

Are Evolving Data Security Norms and Ethical Considerations Reshaping Service Models?

As the volume and sensitivity of stored genetic material increase, so do concerns around data security, ethical governance, and patient consent—factors that are reshaping how DNA and RNA banking services operate. The inherently personal and immutable nature of genetic data raises significant questions about privacy, ownership, and misuse, prompting regulatory authorities worldwide to strengthen compliance frameworks. Legislation such as the General Data Protection Regulation (GDPR) in Europe and HIPAA in the U.S. impose strict guidelines on the collection, storage, and usage of genetic material, requiring service providers to implement robust data encryption, access controls, and traceability protocols. Moreover, ethical biobanking now demands dynamic consent models, where participants are continually informed about how their samples are being used, and can opt in or out of specific research initiatives. These changes are encouraging the adoption of blockchain-based data management systems and biometric authentication to ensure sample provenance and protect against unauthorized access. Service providers are also investing in staff training and institutional review board (IRB) collaborations to ensure that ethical standards are embedded throughout the sample life cycle. Additionally, there`s a rising trend toward community engagement and transparency in research outcomes, especially when collecting samples from indigenous or underrepresented populations. This ethical evolution is not merely a compliance exercise but a strategic imperative—institutions that prioritize ethical integrity and data security are increasingly viewed as more credible and desirable partners for international research collaborations and funding opportunities. These dynamics are not only transforming service delivery models but are also elevating the strategic value of DNA and RNA banking services in the broader research and diagnostics supply chain.

Is Commercialization Driving Innovation and Accessibility in Biobanking Services?

The DNA and RNA banking market is undergoing a profound shift from academic and institutional dominance toward a more commercial, service-oriented model that is making biobanking more accessible and dynamic. Historically, biobanks were primarily affiliated with academic research centers and government institutions, but the growing commercial interest in genetic data has led to the emergence of private biobanking companies offering scalable and on-demand storage services. These services are increasingly tailored for a broad array of clients—including pharmaceutical companies, contract research organizations (CROs), fertility clinics, and even direct-to-consumer (DTC) genetic testing firms. This commercialization wave is driving investments into state-of-the-art storage technologies such as vapor-phase liquid nitrogen systems, automated sample retrieval robotics, and integrated laboratory information management systems (LIMS). Moreover, biobanking services are being bundled with value-added solutions like nucleic acid extraction, quality control assays, data analytics, and even sample logistics management, offering a full-spectrum service ecosystem to clients. Cloud-based sample tracking platforms now enable real-time inventory access, while interoperability with research databases and electronic health records (EHRs) is improving sample utility in clinical applications. Cross-border collaborations and centralized biobanking networks are also gaining traction, allowing researchers to access geographically and ethnically diverse genetic repositories without logistical barriers. The competitive landscape is becoming increasingly innovation-driven, with market players differentiating through faster turnaround times, higher sample quality assurance, and customizable service models. This shift is democratizing access to high-quality biobanking services, enabling even small labs and startups to participate in cutting-edge genomic research without having to invest in their own storage infrastructure.

What Are the True Growth Catalysts Behind the DNA & RNA Banking Services Market?

The growth in the DNA and RNA banking services market is driven by several factors grounded in scientific advancements, evolving end-user needs, and technological infrastructure. Foremost, the surge in genomic and transcriptomic research across academic, clinical, and commercial settings is creating consistent demand for secure and scalable storage of nucleic acids. This demand is magnified by the widespread adoption of next-generation sequencing (NGS) and other high-throughput molecular biology techniques that generate vast volumes of genetic material requiring long-term preservation. Additionally, pharmaceutical and biotech companies are leveraging these services to build comprehensive genetic datasets that support targeted drug development and personalized therapy approaches. Another crucial driver is the increasing reliance on biobanked samples in large-scale epidemiological studies and national genome initiatives that aim to decode genetic diversity and health patterns across populations. Furthermore, the growing use of RNA-based applications—such as mRNA vaccine development and transcriptomic profiling—has underscored the need for ultra-low temperature storage systems with strict RNA integrity preservation. Changing consumer behavior is also playing a role; the popularity of at-home genetic testing kits has led to a proliferation of consumer-generated samples requiring safe, long-term storage options, which has opened new avenues for biobanking services. At the technological level, the integration of AI and machine learning into biobank data management is enabling predictive analytics and smarter resource allocation. Finally, strategic collaborations between public health organizations, private service providers, and academic institutions are fostering standardized practices and broader global accessibility to stored genetic materials. These converging drivers are collectively shaping a resilient and fast-expanding market for DNA and RNA banking services, positioning it as a critical enabler of the next generation of healthcare and biomedical innovation.

SCOPE OF STUDY:

The report analyzes the DNA & RNA Banking Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Service (Transportation Service, Processing Service, Storage Service, Quality Control Service, Data Storage, Other Services); Specimen (Blood Specimen, Buccal Swabs & Hair Follicles Specimen, Other Specimens); Application (Therapeutics Application, Drug Discovery & Clinical Research Application, Clinical Diagnostics Application, Other Applications); End-Use (Academic Research End-Use, Pharma & Biotech Companies End-Use, Hospitals & Diagnostic Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

• 23andMe, Inc.
• AstridBio Ltd.
• Biomatrica, Inc.
• Brooks Life Sciences
• Coriell Institute for Medical Research
• deCODE genetics
• DNA Genotek Inc.
• EasyDNA
• Genetic Services of America
• GenVault Corporation
• GoodCell
• Infinity Biologix
• LGC Biosearch Technologies
• MedGenome Inc.
• National Center for Biotechnology Information (NCBI)
• PreventionGenetics
• ProteoGenex
• Qiagen N.V.
• Sampled (formerly RUCDR Infinite Biologics)
• Thermo Fisher Scientific, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.